According to results from the phase III BELINDA trial, patients with relapsed/refractory aggressive B-cell non-Hodgkin ... Mosunetuzumab was safe and efficacious for patients with heavily pretreated relapsed and/or refractory B-cell ... Patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who received second-line treatment with ...